Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Immunogenicity and Lot Comparability of DAPTACEL in Infants
NCT00662870Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2001
- Primary completion
- Jan 2004
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of diphtheria and tetanus toxoids and acellular pertussis adsorbed in diphtheria, Tetanus and pertussis (4 arms), sponsored by Sanofi. Primary endpoints: Immune Response to DAPTACEL and Immune Response to PRP-T Antigen. Started May 2001; status: completed.
02
Drugs
diphtheria and tetanus toxoids and acellular pertussis adsorbed
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT00662870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662870.